Actively Recruiting
Discovering Outcomes in Clonal Hematopoiesis: The Clonal Hematopoiesis and Inflammation in VasculaturE (CHIVE) Registry and Biorepository
Led by Vanderbilt-Ingram Cancer Center · Updated on 2024-11-22
800
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the relationship between clonal hematopoiesis (CH) and various health conditions, focusing on its link to increased risks of certain cancers and heart disease. This observational study aims to better understand clinical outcomes, cardiovascular features, and the risk of blood cancers in patients with CH or those at higher risk for CH. The study also seeks to create a biorepository of patient samples to support further research on CH's natural history. Participants will be involved in the CHIVE Registry and Biorepository, where they will provide blood and saliva samples, and if already undergoing the procedure, bone marrow samples as well. The study will follow participants for up to approximately 120 months to collect data and samples that help characterize the clinical impact of CH and related conditions. During the study, participants will undergo sample collections and provide informed consent. Researchers will evaluate the development and prognosis of hematologic malignancies and cardiovascular risk factors associated with CH. The long-term follow-up allows for ongoing assessment of health outcomes related to CH mutations, supporting a deeper understanding of its effects over time.
CONDITIONS
Brief Title
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient 18 years old or older at the time of consent
- Able to provide informed consent
- Diagnosed with idiopathic cytopenia (ICUS), idiopathic cytoses, clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP), or at higher risk for clonal hematopoiesis such as those with solid tumors or cardiovascular disease
You will not qualify if you...
- Unable to provide informed consent
- Diagnosis of active hematologic malignancy such as CMML, AML, MDS, or MPN
- History of hematologic malignancy is allowed if in complete remission (e.g., previous myeloma or lymphoma)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 120 months
Participants provide samples including blood, saliva, and bone marrow if already undergoing collection, to support research on clonal hematopoiesis and associated conditions.
Sample collections occur as participants undergo routine care
Duration - Up to approximately 120 months
Participants are observed over time to better understand clinical outcomes, cardiovascular phenotypes, and risk related to clonal hematopoiesis.
Trial Site Locations
Total: 1 location
1
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States, 37203
Actively Recruiting
Research Team
V
Vanderbilt-Ingram Services for Timely Access
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here